

Draft Guidance on Diflunisal

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Diflunisal

Form/Route: Tablet/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
Design: Single-dose, two-way crossover in-vivo
Strength: 500 mg
Subjects: Healthy males and nonpregnant females, general population
Additional Comments: The subjects should have no history of any cardiovascular and gastrointestinal diseases and have no known allergy to the aspirin or any other anti-inflammatory drugs.

2. Type of study: Fed
Design: Single-dose, two-way crossover in-vivo
Strength: 500 mg
Subjects: Healthy males and nonpregnant females, general population.
Additional Comments: Please refer to the Amantadine Hydrochloride Tablet Draft Guidance for additional information regarding fed studies.

Analytes to measure (in appropriate biological fluid): Diflunisal in plasma

Bioequivalence based on (90% CI): Diflunisal

Waiver request of in-vivo testing: Not applicable

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.